Andreas L Petzer

Summary

Affiliation: University of Innsbruck
Country: Austria

Publications

  1. ncbi High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration
    Andreas L Petzer
    Universitatsklinik Innsbruck, Abteilung für Hämatologie and Onkologie, Innsbruck, Austria
    J Hematother Stem Cell Res 11:293-300. 2002
  2. ncbi Low concentrations of STI571 in the cerebrospinal fluid: a case report
    Andreas L Petzer
    Abteilung für Hämatologie and Onkologie, Universitatsklinik Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Br J Haematol 117:623-5. 2002
  3. ncbi Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports
    Andreas L Petzer
    Division of Haematology and Oncology, University Hospital, Innsbruck, Austria
    Blood 99:4632-3. 2002
  4. ncbi Hematopoietic stem cells in chronic myeloid leukemia
    Andreas L Petzer
    Stem Cell Laboratory, Division of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
    Arch Med Res 34:496-506. 2003
  5. ncbi High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial
    Andreas L Petzer
    Central European Leukemia Study Group, Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
    Haematologica 97:1562-9. 2012
  6. ncbi Expansion of mobilized peripheral blood progenitor cells under defined culture conditions rsing CD34+CD71-CD45- cells as a starting population
    Nicolas H Zech
    Stem Cell Laboratory, Division of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
    J Hematother Stem Cell Res 12:367-73. 2003
  7. ncbi Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells
    Johannes Clausen
    Tumor Biology and Angiogenesis Laboratory, Division of Hematology and Oncology, University Hospital, Innsbruck, Austria
    Immunobiology 207:85-93. 2003
  8. ncbi High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study
    Andreas L Petzer
    Central European Leukemia Study Group, Internal Medicine V, Haematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
    Haematologica 95:908-13. 2010
  9. ncbi In vivo release of vascular endothelial growth factor from colorectal carcinomas
    Eberhard Gunsilius
    Division of Hematology and Oncology, University of Innsbruck, Austria
    Oncology 62:313-7. 2002
  10. ncbi Blood levels of vascular endothelial growth factor in obstructive sleep apnea-hypopnea syndrome
    Eberhard Gunsilius
    Blood 99:393-4. 2002

Detail Information

Publications11

  1. ncbi High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration
    Andreas L Petzer
    Universitatsklinik Innsbruck, Abteilung für Hämatologie and Onkologie, Innsbruck, Austria
    J Hematother Stem Cell Res 11:293-300. 2002
    ....
  2. ncbi Low concentrations of STI571 in the cerebrospinal fluid: a case report
    Andreas L Petzer
    Abteilung für Hämatologie and Onkologie, Universitatsklinik Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Br J Haematol 117:623-5. 2002
    ..These are the first data demonstrating a low penetration of orally administered STI571 into the CSF in humans...
  3. ncbi Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports
    Andreas L Petzer
    Division of Haematology and Oncology, University Hospital, Innsbruck, Austria
    Blood 99:4632-3. 2002
    ..5 +/- 0.6 microSv per exposure) seems to be harmless for hematopoietic stem cells, which should simplify the international transport of stem cell grafts...
  4. ncbi Hematopoietic stem cells in chronic myeloid leukemia
    Andreas L Petzer
    Stem Cell Laboratory, Division of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
    Arch Med Res 34:496-506. 2003
    ..This has provided seminal insights into the molecular and cellular biology of leukemia and also of the process of normal hematopoiesis. CML has become a fascinating model disease for malignancy in general...
  5. ncbi High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial
    Andreas L Petzer
    Central European Leukemia Study Group, Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
    Haematologica 97:1562-9. 2012
    ..The potential benefit of initial dose intensification of imatinib in pre-treated patients with chronic phase chronic myeloid leukemia remains unknown...
  6. ncbi Expansion of mobilized peripheral blood progenitor cells under defined culture conditions rsing CD34+CD71-CD45- cells as a starting population
    Nicolas H Zech
    Stem Cell Laboratory, Division of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
    J Hematother Stem Cell Res 12:367-73. 2003
    ..The data presented should allow clinical manipulation (purging) and expansion procedures with mobilized PBPC harvests without the loss of primitive progenitor cells and could be made applicable for large-scale clinical expansion...
  7. ncbi Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells
    Johannes Clausen
    Tumor Biology and Angiogenesis Laboratory, Division of Hematology and Oncology, University Hospital, Innsbruck, Austria
    Immunobiology 207:85-93. 2003
    ..These findings should help optimizing the ex-vivo generation of large numbers of cytotoxic effector cells for immunotherapy...
  8. ncbi High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study
    Andreas L Petzer
    Central European Leukemia Study Group, Internal Medicine V, Haematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
    Haematologica 95:908-13. 2010
    ..Imatinib 400 mg/day is the standard treatment for patients with chronic phase chronic myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic and molecular responses with higher doses of imatinib...
  9. ncbi In vivo release of vascular endothelial growth factor from colorectal carcinomas
    Eberhard Gunsilius
    Division of Hematology and Oncology, University of Innsbruck, Austria
    Oncology 62:313-7. 2002
    ....
  10. ncbi Blood levels of vascular endothelial growth factor in obstructive sleep apnea-hypopnea syndrome
    Eberhard Gunsilius
    Blood 99:393-4. 2002
  11. ncbi Ex vivo expansion of long-term culture initiating marrow cells by IL-10, SCF, and IL-3
    Felix Keil
    Department of Internal Medicine I, Bone Marrow Transplantation Unit, University of Vienna, Vienna, Austria
    Transfusion 42:581-7. 2002
    ..This should be an attractive model for in vitro purging, gene transfer, or expansion of progenitor cells to allow rapid engraftment after myeloablative chemotherapy...